Kim Fox

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +9

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

Kim Fox, Ian Ford, Philippe Gabríel Steg et al. · The Lancet · 2008 · 1.1K citations · Full text

Cardiovascular Disease, Antihypertensive Therapy, Clinical Trials +9

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

Kim Fox, Ian Ford, Philippe Gabríel Steg et al. · The Lancet · 2008 · 782 citations

Heart Rate, Cardiovascular Disease, Health Policy +9

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry

Philippe Gabríel Steg, Nicola Greenlaw, Jean‐Claude Tardif et al. · European Heart Journal · 2012 · 651 citations · Full text

Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina

Jean‐Claude Tardif, Ian Ford, Michał Tendera et al. · European Heart Journal · 2005 · 572 citations · Full text